Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
J DierksMarcia P GasperszA BelkouzJeroen L A van VugtR J S CoelenJ W B de GrootA J Ten TijeW G MeijerJ F M PruijtT van VoorthuizenD J van SpronsenM RentinckD Ten OeverJ M SmitH M OttenT M van GulikJ W WilminkBas Groot KoerkampH KlümpenPublished in: Acta oncologica (Stockholm, Sweden) (2017)
First-line gemcitabine and cisplatin is an effective and safe treatment for patients with unresectable BTC who do not meet the eligibility criteria for the ABC-02 trial. Median OS, PFS and treatment side effects were comparable between the patients who received chemotherapy (group I vs. group II).